Actively Recruiting
Study of Topical Erythromycin and Clindamycin to Reduce Inflammation in Adults with Mild to Moderate Facial Acne
Led by Centre for Human Drug Research, Netherlands · Updated on 2019-03-20
30
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combined bacteriostatic and immune system effects of two topical antibiotics, erythromycin and clindamycin, in people with mild to moderate inflammatory acne vulgaris. This Phase 4 randomized study aims to deepen understanding of how these treatments impact acne through detailed skin assessments and advanced imaging and biomarker analysis. The trial is sponsored by the Centre for Human Drug Research in the Netherlands. Participants are randomly assigned to one of three groups erythromycin 4% topical gel, clindamycin 1% topical lotion, or a 70% topical ethanol solution as a placebo comparator. Each treatment is applied twice daily for four weeks. The study is evaluator-blinded, meaning the person assessing the outcomes does not know which treatment was given. The trial includes comprehensive skin evaluations and biopsies to assess treatment effects. During the study, participants undergo frequent assessments including lesion counts, global acne evaluations, patient-reported outcomes, standardized facial photography, sebum measurements, laser imaging of skin perfusion, optical coherence tomography, and analysis of skin and fecal microbiota. These measures are taken at multiple time points from the start through six weeks. Participants also provide facial skin biopsies at baseline and after 28 days. The total duration includes follow-up visits to monitor changes and safety.
CONDITIONS
Brief Title
Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients
Research Team
R
Robert Rissmann, PharmD, PhD
D
Diana Noort
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here